Genelux (GNLX)

• Market cap: $119M
• 1 day: -2.92%
• 5 days: -6.34%
• 1 month: -38.71%
• 3 months: -66.58%
• 6 months: -24.65%
• Year to date: -41.54%
• 1 year: -32.32%
• 5 years: -56.75%
• 10 years: -56.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Employees: 24